Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS Congress

Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041

MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectivelyData Presented at ATS Showed

Savara Q2 EPS $(0.16) Misses $(0.14) Estimate

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14) per share from the

Savara Announces European And Australian Patents Granted Covering MOLBREEVI Liquid Formulation, Securing Protection Through March 2041